Human prealbumin fraction: effects on cell-mediated immunity and tumor rejection.
The effect of human prealbumin fraction as allogeneic cell-mediated immunity in primary sensitization cultures of murine spleen cells was studied by 3H-thymidine uptake and specific 51Cr release assays. Prealbumin caused a dose-dependent augmentation of these responses. Human serum albumin, bovine serum albumin, and calf-thymosin fraction 5 had little effect. Prealbumin was active when added on day 0 or 1 but not thereafter. Prealbumin added to effector cells from immunized mice did not change their lytic activity. Prealbumin, but not human serum albumin or thymosin fraction 5, augmented secondary cell-mediated immunity in culture after primary immunization in mice. A slow growing mammary tumor line, which originated as a spontaneous mammary tumor in a DBA/2 HaDD breeder mouse, initially grows in 100% of DBA/2J mice but is then rejected in 10-20% of them. When prealbumin (59 microgram/day) was given subcutaneously for 2 weeks to DBA/2J mice and the tumor implanted 2 weeks later. 78% of the mice rejected the tumor and were then resistant to a rechallenge.
D000818:Animals; D002478:Cells, Cultured; D002860:Chromium Radioisotopes; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D011228:Prealbumin / Q000494:pharmacology*; D012709:Serum Albumin / Q000494:pharmacology*; D013154:Spleen / Q000166:cytology; D013936:Thymidine / Q000378:metabolism; D013947:Thymosin / Q000494:pharmacology
D002860:Chromium Radioisotopes; D011228:Prealbumin; D012709:Serum Albumin; D013947:Thymosin; D013936:Thymidine